Clinical Trial

Unravelling Intestinal Fibrosis in Ulcerative Colitis

Study acronym: INTERACT
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 3, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main objectives are: (i) to identify candidate fibrotic cellular pathways in UC patients treated with a JAK inhibitor filgotinib), and (ii) to detect and monitor in vivo fibrosis in UC patients using FAPi-PET/CT imaging
Trial Details
NCT Number NCT06604273
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Fibroblast Activation Protein Inhibitor
Enrollment 10 participants
Start Date 2024-04-03
Primary Completion 2025-10-03 (estimated)
Study Completion 2026-04-03 (estimated)
Updated on ClinicalTrials.gov 2024-09-19